Introduction
Incomplete recovery of myocardial tissue perfusion despite successful opening of the culprit artery by primary percutaneous coronary intervention (PPCI) occurs in approximately half of patients with STelevation myocardial infarction (STEMI). 1, 2 The two major underlying pathologies in this complex process mainly caused by ischaemia-reperfusion injury are microvascular obstruction (MVO) and/or extravasation of erythrocytes leading to intramyocardial haemorrhage (IMH). [3] [4] [5] [6] MVO detected by late gadolinium cardiac magnetic resonance (CMR) has been shown to be a marker of major prognostic relevance in patients with revascularized STEMI in numerous outcome studies. 7, 8 However, it is still unclear whether IMH represents a simple bystander of infarct severity or a marker of adverse prognosis beyond left ventricular ejection fraction (LVEF), infarct size, and especially MVO. [9] [10] [11] Indeed, only few small-sized single-centre outcome studies were performed so far and they reported conflicting results regarding the prognostic value of IMH in the presence of other infarct characteristics. 2, 9, [12] [13] [14] Current evidence is further limited by a significant heterogeneity in the CMR imaging techniques applied to visualize IMH. Most clinical outcome studies (three out of four) used T2-weighted imaging [short tau inversion recovery (T2-STIR)], rather than T2*-weighted imaging which, however, is the reference standard for the assessment of IMH in vivo. [15] [16] [17] [18] [19] A recent study by Hansen et al. 20 even suggests that conventional T2-STIR imaging does not allow for discrimination between MVO and IMH in a porcine model of myocardial ischaemiareperfusion. Carrick et al. 2 performed the first and only study that examined the impact of IMH determined by T2* imaging on clinical events. In this study, MVO and IMH followed distinct time courses after STEMI and IMH was more closely associated with adverse outcomes than MVO, suggesting a different prognostic significance. As such, there is still controversy with regard to how best image IMH and to its independent and potential incremental value when assessed by T2* imaging for the prediction of hard clinical events. This was also nicely pointed out in a recent editorial by Arheden 10 who concluded that we still lack information on the independent prognostic power of T2* imaging for determination of IMH. The objective of this study was therefore to comprehensively investigate the prognostic significance of IMH specifically depicted by T2* imaging in a multicentre population of STEMI patients treated by PPCI.
Methods

Study design
Consecutive STEMI patients undergoing PPCI within 12 h after symptom onset at two tertiary care centres (University Heart Center Leipzig and University Heart Center Innsbruck) were prospectively included in the haemorrhage assessed by Cardiac Magnetic Resonance in ST-elevation myocardial infarction (HEM-CMR) study. Exclusion criteria were an estimated glomerular filtration rate <30 mL/min/1.73 m 2 , contraindications to CMR, and haemodynamic instability not allowing CMR acquisition. The primary clinical endpoint [major adverse cardiac events (MACE)] was defined as a composite of all cause death, non-fatal reinfarction and the occurrence of new heart failure after hospital discharge for the index event. Follow-up was conducted at 12 months via an outpatient visit. To avoid double counting of patients with more than one event, each patient contributed only once to the MACE endpoint (death>reinfarction>congestive heart failure). The study was performed in accordance with the Declaration of Helsinki and was approved by both local ethics committees.
Cardiac magnetic resonance imaging
Patients underwent CMR on 1.5 T scanners within the first week after PPCI. The CMR protocol and standardized post-processing for determination of left ventricular (LV) dimensions and function as well as standard infarct characteristics (infarct size, presence and extent of MVO) have been published previously. 21, 22 An established CMR core laboratory involving observers blinded to all other clinical data performed image analysis. Reproducibility, inter-as well as intra-observer variability of the CMR core laboratory were reported previously. 23 IMH was assessed by T2* quantification using a breath-hold, cardiac gated gradient echo sequence with eight echoes obtained in three matching short-axis slices before administration of the contrast agent. A motion correction algorithm was applied to reduce movement artefacts. Typical imaging parameters were: echo time-= 2.02-16.3 ms, time to repetition = 948.8 ms, flip angle = 20 , bandwidth = 814 Hz/pixel, matrix = 256 Â 110 pixels, spatial resolution = 1.6 Â 1.6 Â 8.0 mm, and slice thickness = 8 mm. Motion corrected, colour-coded T2*-maps were automatically inline generated by fitting signal intensities at each image pixel with an exponential model for the given echo times. Evaluation of the maps was carried out on IMPAX EE workstations (Agfa Healthcare, Bonn, Germany) by manually outlining endo-and epicardial contours with taking care to exclude subendocardial blood and subepicardial tissue to avoid partial volume effects. As previously reported, 2, 17, 24, 25 IMH was defined as a region of hypointense core within the infarcted area with reduction of T2* signal intensities below 20 ms. 
Statistical analysis
Results
Study population and patient characteristics
Out of 278 STEMI patients enrolled, 264 (95%) had complete data including CMR scans with evaluable T2* imaging ( Figure 1 ). The risk profile as assessed by the TIMI-risk score did not significantly differ between those with missing CMR data and those included in the final study cohort (P = 0.15). Patients were dichotomized according to the presence (n = 60, 23%) or absence (n = 204, 77%) of IMH. Baseline characteristics as well as CMR findings of the overall population as well as according to IMH status are presented in Table 1 . CMR imaging was performed in median 3 days (interquartile range 2-4) after STEMI in both groups (P = 0.48). The presence of IMH was significantly associated with lower LVEF and worse infarct characteristics ( Table 1) . CMR imaging examples are shown in Figure 2 . The absence of both MVO and IMH was detected in 109 patients (41%), whereas 95 patients (36%) had MVO only, 55 patients (21%) had IMH and MVO, and 5 patients (2%) had IMH without MVO.
Baseline associates of intramyocardial haemorrhage
In a binary logistic regression analysis including baseline characteristics, anterior infarction [odds ratio (OR) 3.1, 95% confidence interval Intramyocardial haemorrhage and prognosis (CI) 1.6-5.8; P = 0.001], and impaired TIMI-flow before PCI (OR 0.5, 95% CI 0.4-0.7; P < 0.001) were multivariable associates of IMH, whereas body mass index, TIMI-risk score and Killip classification were not.
Intramyocardial haemorrhage and clinical outcome
Nineteen patients (7.2%) experienced a MACE event [death, n = 6 (2.3%); new congestive heart failure, n = 9 (3.4%); reinfarction, n = 4 (1.5%)]. Patient characteristics according to major adverse cardiac events are shown in Table 2 . Patients with IMH had a significantly higher MACE rate compared with patients without IMH [n = 9 (15%) vs. n = 10 (4.9%), hazard ratio 3.4, 95% CI 1.3-8.9; P = 0.008]. Accordingly, Kaplan-Meier curves demonstrated a significantly lower 12 month MACE-free survival rate in patients with IMH than in patients without IMH (log-rank, P = 0.009) ( Figure 3 ). The presence of MVO (hazard ratio 1.7, 95% CI 0.6-4.4; P = 0.308] was not significantly associated with MACE. However, the extent of MVO showed a significant association with MACE (hazard ratio 1.1, 95% CI 1.0-1.2; P = 0.029). Further stratification of patients in (i) no IMH present and no MVO present, (ii) MVO present but no IMH present, and (iii) IMH present showed a stepwise increase of MACE risk (P = 0.025, Figure 4 ). With respect to the number of patients and the number of events observed, two multivariable Cox models were considered: (i) a clinical model with TIMI-risk score and IMH and (ii) a CMR model with LVEF and all infarct characteristics including IMH ( Table 3) . Presence of IMH emerged as independent predictor of MACE in the clinical (hazard ratio 2.7, 95% CI 1.1-6.6; P = 0.032) as well as in the CMR model (hazard ratio 3.1, 95% CI 1.2-7.7; P = 0.013).
Intramyocardial haemorrhage and incremental prognostic value
According to the CMR score, 65 patients (25%) were in the lowest risk class (0 points), 102 patients (39%) were in the intermediate risk class (1-2 points) , and 97 patients (37%) in the high risk class (3-4 points). There was a stepwise increase of MACE rates from 3% (n = 2) in the lowest risk class to 5% (n = 5) in the intermediate risk class and to 12% (n = 12) in the high risk class (P = 0.042) ( Figure 5) . In reclassification analysis, applying risk levels of <3%, 3% to <5%, 5% to <12%, and > _12%, the inclusion of IMH to a risk model comprising LVEF, infarct size and MVO led to an NRI of 0.42 (95% CI 0.11-0.73, P = 0.009). In detail, 37% of the cases (n = 7) and 5% of the non-cases (n = 12) were net correctly reclassified. The continuous NRI was 0.53 (95% CI 0.07-0.99, P = 0.024). Another reclassification model based on the addition of the CMR score to the TIMI-risk score resulted in an NRI of 0.24 (95% CI 0.01-0.49, P = 0.04). The continuous NRI was 0.52 (95% CI 0.07-0.96, P = 0.02).
Discussion
The main findings of our analysis were as follows: (i) IMH was independently associated with MACE at 12 months after STEMI; (ii) IMH was more closely associated with MACE than MVO; (iii) IMH added incremental prognostic information to clinical risk factors and other established CMR prognosis markers including infarct size and MVO. Consequently, determination of IMH by T2* imaging may be relevant as important prognostic measure as well as major therapeutic target when caring for patients with STEMI. Larger clinical studies are warranted to further elucidate these hypotheses.
Intramyocardial haemorrhage and prognosis
IMH often occurs even after successful reperfusion in acute myocardial infarction and is associated with more extensive myocardial necrosis. 2, 13, 14, 26, 27 In our study, infarct severity by CMR was also greater in patients with IMH when compared with those without. Previous studies involving STEMI patients have additionally shown that IMH is associated with incomplete functional recovery 27, 28 and adverse cardiac remodelling. 14, 26, 27 Studies focusing on the direct impact of IMH on adverse cardiovascular outcomes are, however, scarce. Amabile et al. 13 included 114 patients and observed a higher rate of adverse events during the first year following STEMI in those with IMH. There was also a non-significant trend towards a higher rate of MACE in patients with IMH and MVO when compared with patients with MVO only. Another study involving 346 patients showed that the inclusion of IMH in addition to clinical variables, LV function and infarct size (but not MVO) provided additive prognostic value for MACE prediction. 12 In contrast, Husser et al. 14 could not
show an incremental predictive value of IMH in addition to a model including other CMR variables. Of note, these studies used conventional T2-STIR rather than T2* imaging for IMH detection, which may have significantly confounded the findings. First, T2-STIR imaging has been shown to have a lower diagnostic accuracy compared with T2* imaging. 15, 18 Second, T2* imaging is more sensitive to paramagnetic effects of haemoglobin byproducts than T2-weighted imaging and more specific for IMH visualization. 15, 24 Third, there is recent evidence from a postmortem study by Jackowski et al. 29 and an animal study by Hansen et al. 20 showing that hypointense signal cores on T2-STIR images might represent pathologies other than IMH, for example, non-edematous infarct tissue. Consequently, IMH is best depicted with the use of T2* imaging despite some existing disadvantages (e.g. off-resonance artefacts), which may have limited the broad application in the past. 19 The study by Carrick et al. 2 is the only study using T2* imaging for IMH assessment. The authors found an association between IMH and MACE, even after adjustment for baseline LV end-diastolic volume. However, this study did not assess whether IMH provides incremental prognostic information in addition to other established CMR infarct characteristics of prognosis. Our study expands the literature by demonstrating a prognostic impact of IMH even in the presence of other adverse infarct characteristics including large infarct sizes and presence or extent of MVO. We were also able to show an incremental prognostic benefit above and beyond clinical risk factors (TIMI-risk score) and CMR parameters of LV function and myocardial damage. The pathophysiological mechanisms linking IMH and worse outcome are not fully understood. A key factor, however, might be a prolonged inflammatory reaction within the infarct zone due to toxic haemoglobin degradation products, which has been shown to impair collagen deposition and scar formation leading to reduced tensile strength and chamber dilatation. 30, 31 Indeed, recent experimental and clinical studies have demonstrated a clear link between IMH and persistence of inadequate inflammatory activity. In a rat model of reperfused myocardial infarction, Ye et al. 32 found intense macrophage recruitment in infarct territories with MVO and IMH. Another study evaluating myocardial tissue of canines subjected to ischaemiareperfusion injury showed an ongoing inflammatory response in the infarct tissue with iron deposits in the chronic phase of haemorrhagic infarcts. 33 The same investigation performed T2* imaging on day 3
and 6 months thereafter in 15 patients receiving PPCI for STEMI and found chronic iron depositions in humans as well. 33 Another study observed that 59% of STEMI patients with baseline IMH as evidenced by T2* mapping had persistent iron within the infarct core at 6 months. 34 Importantly, persistent iron was associated with neutrophil count, LV remodelling and worsening function. 34 The distinct inflammatory reaction, which may be different for IMH and MVO, could therefore be crucial in the understanding of worse outcome. There is also evidence suggesting detrimental effects of chronic iron deposition within the infarcted myocardium on the electrical behaviour of the heart. 26, 35 IMH may thus evolve as a substrate for ventricular arrhythmias in the post-infarction period and this feature is likely to contribute in part to a higher mortality rate in these patients.
Association between intramyocardial haemorrhage and microvascular obstruction
Although several previous studies suggested that IMH occurs only in the presence of MVO, 9 there is also evidence indicating that a minority of patients may develop IMH without MVO. 14, 17 In the present study, almost all patients with IMH also had MVO; however, five patients (2%) exhibited IMH without MVO. It has been speculated that this may be due to the high sensitivity of T2* imaging allowing the detection of even very small amounts of IMH with MVO that is missed by late-gadolinium enhanced imaging. 17 Alternatively, the detection of IMH without MVO may be explained due to passive diffusion of gadolinium contrast agent into the areas of MVO, causing a decreased size or even masking of MVO when using late gadolinium sequences. 6 For instance, in an analysis by Bekkers et al., 36 it was
shown that compared with early gadolinium enhancement imaging, MVO presence with assessment of late gadolinium enhancement imaging disappeared in 9% of patients. Finally, despite the high sensitivity of T2* imaging for IMH detection, it is also sensitive to artefacts, such as off-resonance artefacts, which can bias the depiction of IMH.
Clinical implications
Although CMR has not been established as routine method to guide therapy after STEMI, it enables important pathophysiological insights and prognostic information. Our observations fill an important knowledge gap by providing a better understanding of the prognostic significance of IMH by T2* imaging in survivors of STEMI. Indeed, IMH revealed by T2* imaging may add incremental prognostic information and is not only a simple bystander of infarct severity. One might therefore speculate that comprehensive tissue characterization by CMR could have a role in the future to personalize treatment and follow-up regimens for these patients. Determination of IMH by T2* imaging at an early stage after STEMI may be a further step in that direction. In contrast to other imaging modalities (e.g. echocardiography or computed tomography), CMR has several advantages. CMR provides objective measurements of LV dimensions and function with no need for radiation exposure and with higher sensitivities and accuracy when compared with echocardiography. 37 The most intriguing application of CMR is, however, the unique opportunity to comprehensively depict infarct-related pathologies (including IMH) that provides prognostic information over and above conventionally used clinical and echocardiographic parameters. 8, 37, 38 Nevertheless, prospective randomized studies are necessary to determine whether early tissues characterization by CMR after STEMI results in improved management and outcomes when compared with standard care. Preservation of the microvasculature from the deteriorating impact of reperfusion might help to protect or reduce the development of IMH after PPCI. Recent preclinical studies looking at the effect of innovative treatment strategies on reperfusion injury have shown promising results. 39 These include therapeutic targeting of known individual components of lethal reperfusion injury including oxidative stress, intracellular calcium overload, mitochondrial permeability transition pore opening, and diverse inflammatory responses. 39 However, the translation from bench to bedside has been largely underwhelming so far. Interestingly, results from a recent CMR imaging study that evaluated the presence of IMH on four occasions (4-12 h, $3 days, 10 days, and 7 months after STEMI) indicate a phase of secondary haemorrhage between day 1 and day 3, which imply that a therapeutic window for attenuation of IMH may exist. 40 This is, therefore, a promising area of research, and our results further underscore that IMH 
Study limitations
Our study population was relatively small and duration of follow-up was restricted to 1 year after STEMI. Although comparable with other studies, 7 the number of observed events was also relatively low. This finding may be partially explained by the exclusion of haemodynamically unstable patients who could not undergo CMR acquisition. Moreover, the association between IMH and individual MACE endpoints cannot be established by the current studies. Our and previous outcome studies 2, 12, 14 evaluated the prognostic value of the presence of IMH but did not assess IMH quantitatively. Although quantification of IMH may be reasonable, it was not possible for the current analysis since full LV coverage for T2* was missing. It would thus be important for future studies to elucidate whether differences in prognostic information exist between depiction and quantification of IMH by T2* imaging. In addition, we may have missed some patients with very small areas of IMH due to the lack of whole heart T2* coverage. CMR scans were performed in median 3 days after STEMI, which is similar to other studies assessing the prognostic value of CMR after STEMI. 7, 8 However, this could have affected the assessment of IMH due to it temporal evolution during the first days after infarction. 40 Infarct core pathology and remote myocardium alterations by quantitative T1 mapping which have been recently described as novel CMR markers with potential for prognostication in STEMI survivors were not assessed.
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Conclusion
Our study suggests that IMH by T2* imaging may be an independent prognostic CMR marker of MACE in revascularized STEMI patients. Therefore, the additional assessment of IMH has potential to identify those at greatest risk for adverse outcome and to serve as therapeutic target for the assessment of novel treatment strategies in acute STEMI.
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